Cheng, AYY, Mauricio, D, Ritzel, R, Al-Sofiani, ME, Bailey, T, Mabunay, MA, Bonnemaire, M, Melas-Melt, L, Mimouni, S, Davies, M. A post-hoc pooled analysis to evaluate efficacy and safety of insulin glargine 300 U/mL in insulin-naïve people with type 2 diabetes with/ without prior use of glucagon-like peptide-1 receptor agonist therapy. DIABETES RESEARCH AND CLINICAL PRACTICE. 2024; 217DOI:10.1016/j.diabres.2024.111871. PMID:39343145. IF:7.400(Q1/1D).

Facundo, AN, Magalhaes, M, Nascimento, GC, Azulay, RS, Santos, RM, Freitas, LA, Nascimento, AGPAC, Rodrigues, VP, Santos, WC, Beckman, AMGS, Abreu, JMF, Silva, RP, Carneiro, EL, Neto, CPO, da Costa, RMG, Corcoy, R, Mato, E, Faria, MS. The expression of VDACs and Bcl2 family genes in pituitary adenomas: clinical correlations and postsurgical outcomes. Frontiers in Endocrinology. 2024; 15DOI:10.3389/fendo.2024.1481050. PMID:39449743. IF:4.600(Q1/3D).

Genua, I, Sardà, H, Pérez, A. Cardiometabolic effects of weight loss. Atencion Primaria. 2024; 56(10)DOI:10.1016/j.aprim.2024.102953. PMID:38705132. IF:1.600(Q2/4D).

Pérez, A. GLP-1 receptor agonists in clinical practice. MEDICINA CLINICA. 2024; 163(5)DOI:10.1016/j.medcli.2024.02.018. PMID:38688736. IF:2.100(Q2/3D).

Somolinos-Simón, FJ, García-Sáez, G, Tapia-Galisteo, J, Corcoy, R, Hernando, ME. Cluster analysis of adult individuals with type 1 diabetes: Treatment pathways and complications over a five-year follow-up period. DIABETES RESEARCH AND CLINICAL PRACTICE. 2024; 215DOI:10.1016/j.diabres.2024.111803. PMID:39089589. IF:7.400(Q1/1D).

Cheng, A, Mauricio, D, Ritzel, R, Al-Sofiani, ME, Bailey, T, Mabunay, M, Bonnemaire, M, Lydie, MM, Mimouni, S, Davies, M. Efficacy and safety of insulin glargine 300 U/mL in insulin-naive people with type 2 diabetes with/without prior use of glucagon-like peptide-1 receptor agonist therapy. DIABETOLOGIA. 2024; 67DOI:. PMID:. IF:10.200(Q1/1D).